secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2023-07-17T23:59:59+00:00
Accession:  0001193125-23-188117
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis reports 6 retinal vasculitis events after SYFOVRE; rate ~0.01% per injection
--------------------------------------------------------------------------------

- Six retinal vasculitis events observed after first SYFOVRE injection, 7-13 days post-dose; no specific lot implicated.
- Estimated event rate ~1 per 10,000 injections (0.01%); approximately 60,000 vials distributed since FDA approval.
- Two events confirmed occlusive, one non-occlusive, three undetermined; etiology unclear, outcomes evolving.
- Zero retinal vasculitis events in clinical trials (>23,000 injections); FDA notified, no action planned at this time.
- Company investigating with ASRS ReST Committee and external specialists; will update as new info emerges.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523188117/0001193125-23-188117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523188117/d510143d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-188117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer